About Sense Biodetection
Sense Biodetection is a company based in Abingdon (United Kingdom) founded in 2014 by Harry Lamble was acquired by Sherlock in February 2023. Sense Biodetection has raised $79.22 million across 6 funding rounds from investors including Gov.uk, Sherlock Biosciences and Mercia. The company has 43 employees. Sense Biodetection offers products and services including Diagnostic Technologies and Innovation Pipeline. Sense Biodetection operates in a competitive market with competitors including GenMark Diagnostics, Stilla Technologies, Silicon Biosystems, NeuMoDx and Biomeme, among others.
- Headquarter Abingdon, United Kingdom
- Employees 43
- Founders Harry Lamble
- SectorsHealthcare
- Email••••••••
- Website sense-bio.com
- Social LinkedIn X
- Acquired by Sherlock (Feb 2023)
- Legal Name Sense Biodetection Limited
- Date of Incorporation 25 Jul, 2013
- Jurisdiction ABINGDON, ENGLAND
- Annual Revenue$14.24 K (USD)0as on Dec 31, 2022
- Net Profit-$36.38 M (USD)1as on Dec 31, 2023
- EBITDA-$38.72 M (USD)7as on Dec 31, 2023
- Total Equity Funding$79.22M (USD)
in 6 rounds
- Latest Funding Round$15M (USD), Series B
Nov 2021
- InvestorsGov.uk
& 7 more
- Employee Count43
- Acquired bySherlock
(Feb 2023)
Products & Services of Sense Biodetection
Sense Biodetection offers a comprehensive portfolio of products and services, including Diagnostic Technologies and Innovation Pipeline.
Tools for bioscience testing and innovation purposes
Systems enhancing medical capabilities through acquisitions
Funding Insights of Sense Biodetection
Sense Biodetection has successfully raised a total of $79.22M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $79.22M
- Total Rounds 6
- Last Round Series B — $15M
- First Round $737,824
(Jun 2016)
- Investors Count 7
All 6 funding rounds of Sense Biodetection with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $15M | Series B | – | Koch Disruptive Technologies | – |
| Apr 2021 | $50M | Series B | – | Koch Disruptive Technologies | |
| Oct 2020 | – | Series B | – | Mercia, Cambridge Innovation Capital | |
| Oct 2019 | $2.31M | Grant | – | – | |
| Oct 2019 | $13.48M | Series A | – | Cambridge Innovation Capital, Earlybird | |
| Jun 2016 | $737,824 | Seed | – | Mercia | – |
8 investors in total: 7 institutional and 1 angel.
Investors in Sense Biodetection
Sense Biodetection has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Gov.uk, Sherlock Biosciences and Mercia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by the venture capital firm. | 2017 | kochdisruptivetechnologies.com | Wichita, United States | |
Venture capital investments are made in life sciences and deep tech. | 2013 | cic.vc | Cambridge, United Kingdom | |
Earlybird is recognized as a venture capital investor focused on early-stage tech companies. | – | earlybird.com | Berlin, Germany | |
- | – | cicplc.co.uk | - | |
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | - | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
JM Jonathan Milner | British angel investor, founder of Abcam, active in biotech and life sciences. | – | unknown_2a0543917deb42029 | - |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | sherlock.bio | Watertown, United States |
Investor details for Sense Biodetection
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sense Biodetection
8 people are tracked at Sense Biodetection (3 in leadership, 5 in board & advisors); the tracked headcount is 43.
| Name | Role | Group |
|---|---|---|
Harry Lamble | Founder & Chief Business Development Officer | Leadership |
Timothy I. Still | CEO | Leadership |
Stappert Jörg | Director of Business Development DACH | Leadership |
John Bishop | Director | Board & advisors |
Rainer Christine | Director | Board & advisors |
Mike Anstey | Director | Board & advisors |
Brett Chugg | Director | Board & advisors |
Heiner Dreismann | Chairman | Board & advisors |
Complete people profiles for Sense Biodetection
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sense Biodetection
4 dated milestones of Sense Biodetection across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sense Biodetection is founded.
- Funding First funding round of $738K.
- Funding Latest funding round, Series B, of $15.0M.
- Exit Acquired by Sherlock.
Competitors of Sense Biodetection
Sense Biodetection operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenMark Diagnostics, Stilla Technologies, Silicon Biosystems, NeuMoDx and Biomeme, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| stillatechnologies.com | 2013 | Villejuif, France | $53.11M | – | Digital PCR solutions for research are developed and analyzed. | |
| siliconbiosystems.com | 1999 | Bologna, Italy | $25.53M | – | Lab-on-a-chip technologies for miniaturized cell-biology testing are developed. | |
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| biomeme.com | 2013 | Philadelphia, United States | $6.2M | 202 | Smartphone-based DNA detection platform is developed for diagnostics. | |
| mesabiotech.com | 2009 | San Diego, United States | $26.8M | 131 | Point-of-care molecular diagnostic kits are developed and supplied. | |
| targetingone.com | 2015 | Haidian, China | $23.19M | – | Micro-droplet digital PCR and diagnostic reagents are manufactured. | |
| dnae.com | 2003 | London, United Kingdom | – | 111 | Semi-conductor-based NGS diagnostics for infectious diseases are offered. | |
| minipcr.com | 2013 | Cambridge, United States | – | 18 | PCR and electrophoresis instruments are developed for laboratory use. |
Detailed competitors of Sense Biodetection
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sense Biodetection
The website of Sense Biodetection (sense-bio.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 33.3% vs previous month
Latest news on Sense Biodetection
Complete news archive for Sense Biodetection
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sense Biodetection
10 companies that operate in the same segment as Sense Biodetection (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sense Biodetection
Sense Biodetection was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Sense Biodetection is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Sense Biodetection is a funded company, having raised a total of $79.22M across 6 funding rounds to date. The company's 1st funding round was a Seed of $737.82K, raised on Jun 2016.
Sense Biodetection has 43 employees.
Annual revenue of Sense Biodetection is $14.24K as on Dec 31, 2022.
Sense Biodetection was founded in 2014 and is based in Abingdon, United Kingdom. Operations focus on the biotechnology sector, where proprietary molecular amplification and device technologies are utilized to enable sensitive detection of specific nucleic acids. Point-of-care diagnostic solutions are offered, supporting rapid molecular testing in clinical and field settings across various applications.
Sense Biodetection's top competitors include GenMark Diagnostics, Stilla Technologies and NeuMoDx.
Sense Biodetection offers Diagnostic Technologies and Innovation Pipeline.
Sense Biodetection has 8 investors. Key investors include Gov.uk, Sherlock Biosciences, Mercia, Koch Disruptive Technologies, and Cambridge Innovation Capital.
Sense Biodetection operates through Sense Biodetection Limited.
Yes. Sense Biodetection was acquired by Sherlock in February 2023.